Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.69USD
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
$1.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,166
52-wk High
$1.89
52-wk Low
$0.74

Chart for

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $248.43
Shares Outstanding(Mil.): 147.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Durect appoints Myriam Theeuwes as senior vice president of clinical development

* Durect appoints Dr. Myriam Theeuwes as senior vice president, clinical development Source text for Eikon: Further company coverage:

Sep 20 2017

BRIEF-Durect Q2 loss per share $0.07

* Durect Corporation announces second quarter 2017 financial results and provides corporate update

Aug 08 2017

BRIEF-Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

* Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

Aug 08 2017

BRIEF-Zogenix and Durect Corp enter into termination agreement

* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing

Aug 03 2017

BRIEF-Durect says ‍on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014​

* Durect - ‍on July 24, Impax Laboratories provided notice to co, that Impax is terminating asset transfer and license agreement dated January 3, 2014​

Jul 28 2017

BRIEF-Durect completes enrollment in persist, phase 3 trial for Posimir

* Durect completes enrollment in Persist, phase 3 trial for Posimir

Jun 22 2017

BRIEF-Durect's collaboration with Sandoz clears HSR review

* Durect's collaboration with Sandoz clears Hart-Scott-Rodino review and is effective

Jun 19 2017

BRIEF-Durect Corp, Sandoz AG sign U.S. development and commercialization agreement for posimir

* Durect Corp - co and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for U.S. for posimir

May 11 2017

BRIEF-Durect Q1 revenue $4.6 million

* Durect Corporation announces first quarter 2017 financial results and provides corporate update

May 10 2017

CORRECTED-Durect, Novartis' Sandoz ink deal to develop non-opioid pain drug

May 8 Durect Corp said on Monday it signed an up to $293 million deal with Swiss drugmaker Novartis AG's Sandoz unit to develop and market Durect's experimental non-opioid pain relief therapy, posimir, in the United States.

May 08 2017

Earnings vs. Estimates